A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019
Carla Pires
Abstract
BACKGROUND: COVID-2019 pandemic lead to a raised interest on the development of new treatments through Artificial Intelligence (AI). AIM: to carry out a systematic review on the development of repurposed drugs against COVID-2019 through the application of AI. METHODS: The Systematic Reviews and Meta-Analyses (PRISMA) checklist was applied. KEYWORDS: , DOAJ and SciELO. Cochrane Library was additionally screened to identify previous published reviews on the same topic. RESULTS: = 1)], 27 studies were included. Among other, the selected studies on new treatments against COVID-2019 were classified, as follows: studies with in-vitro and/or clinical data; association of known drugs; and other studies related to repurposing of drugs. CONCLUSION: Diverse potentially repurposed drugs against COVID-2019 were identified. The repurposed drugs were mainly from antivirals, antibiotics, anticancer, anti-inflammatory, and Angiotensin-converting enzyme 2 (ACE2) groups, although diverse other pharmacologic groups were covered. AI was a suitable tool to quickly analyze large amounts of data or to estimate drug repurposing against COVID-2019.